Search results
Showing 8821 to 8835 of 8902 results
NICE recommends a weekly injection for treating growth failure in children
This recommendation comes from a pilot to develop simpler, faster evaluations for the appraisal of some treatments.
New NICE quality standard identifies improvements in UTI diagnosis for women
Health professionals should diagnose women under 65 with a urinary tract infection (UTI) if they have two or more key urinary symptoms.
Nine treatment options to be made available for adults with depression or an anxiety disorder
Six digitally enabled therapies for adults with anxiety disorders and three for adults with depression have been recommended for use in the NHS.
NICE recommends two CAR-T therapies, both given as one-off infusions, to treat aggressive forms of blood cancer.
We've updated our health inequalities web resource so that it maps NICE guidance to frameworks for children and young people.
An early introduction to NICE’s ongoing activity in virtual wards
How 'surrogate outcomes' influence long-term health outcomes
NICE working with international organisations to develop guidance.
NICE’s latest quality standard published today (16 March 2022) helps improve the diagnosis, assessment, and prevention of fetal alcohol spectrum disorder (FASD).
Statins a choice for more people to reduce risk of heart attacks and strokes
New evidence on the safety of statins means more people could benefit from them, new NICE draft guidance says.
NICE launches second consultation on genetic testing to guide treatment after a stroke
People could be offered a genetic test in the immediate period after having a stroke to help identify the most suitable treatment to reduce their risk of further strokes.
NICE's deputy chief executive, Jonathan Benger, talks about our new approach to prioritisation.
How NICE is ensuring its topic prioritisation decisions are grounded in lived experience
Simon Denegri discusses NICE’s commitment to involving the public voice in its work and decisions.
NICE collaboration on streamlined licensing and patient access process for new medicines
Companies can now submit medicines for the new Innovative Licensing and Access Pathway (ILAP) following close collaboration between the NICE, drug regulators, the NHS and equivalent organisations in Scotland.
Pembrolizumab plus chemotherapy not recommend for triple negative breast cancer
Draft guidance published today (8 March 2022) by NICE does not recommend pembrolizumab plus chemotherapy for treating triple negative breast cancer
How NICE manages the potential conflicts of interests of patient experts
People with lived experience provide valuable insight into the impact of NICE’s’ guidance and advice.